Steadybase.

Seaport Therapeutics, Inc.

Website Investor relations LinkedIn
  • SPTX · Nasdaq
  • Pharmaceutical Preparations
  • Boston, MA
  • CIK 0002042347

Updated from SEC filings through

Top things to know

Next earningsDecember 28, 2026Estimated from past filings
Latest 8-KResults of operations and financial conditionFiled November 2, 2026

Executives

What leadership is saying

“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial”

Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
Earnings press release (8-K Ex. 99.1), filed November 2, 2026

Seaport Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Boston, MA. It trades as SPTX on Nasdaq. Daphne Zohar is Co-Founder and Chief Executive Officer at Seaport Therapeutics.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Daphne Zohar
Founder & CEO Seaport Therapeutics
Co-Founder and Chief Executive Officer at Seaport Therapeutics 8-K, November 2, 2026
Lauren White Chief Financial Officer Form 4, May 4, 2026
Antony Loebel
Innovative Pharmaceutical Executive I Extensive Clinical Development Expertise as Chief Medical Officer I Deep Neuropsychiatric R&D and Commercial Experience I
Chief Medical Officer Form 4, May 4, 2026
Michael Cunyuan Chen Chief Scientific Officer Form 4, May 4, 2026
Lana Gladstein
General Counsel
General Counsel Form 4, May 4, 2026

Shares and governance

Shares outstanding 53.5 million (as of October 27, 2026) 10-Q, November 2, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 2, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 3, 2026 Denice Torres
Director
Buy 5,000 $99K Form 4, November 4, 2026
June 22, 2026 Robert J. Hombach
Director
Buy 13,000 $236K Form 4, June 24, 2026

Recent 8-K events

Frequently asked questions about Seaport Therapeutics, Inc.

What does Seaport Therapeutics, Inc. do?
Seaport Therapeutics, Inc. is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in Boston, MA.
Who is the CEO of Seaport Therapeutics, Inc.?
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics, as named in a 8-K filed November 2, 2026.
Who is the CFO of Seaport Therapeutics, Inc.?
Lauren White, Chief Financial Officer, as named in a 4 filed May 4, 2026.
Where is Seaport Therapeutics, Inc. headquartered?
Boston, MA.
What is Seaport Therapeutics, Inc.'s stock ticker?
SPTX on Nasdaq.
What industry is Seaport Therapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Seaport Therapeutics, Inc.'s website?
seaporttx.com. Investor relations: https://investors.seaporttx.com/.
When does Seaport Therapeutics, Inc. report earnings next?
December 28, 2026. This is an estimate from past filing dates, not a confirmed date.
Is Seaport Therapeutics, Inc. a public company?
Yes. Seaport Therapeutics, Inc. files with the SEC under CIK 0002042347 and trades as SPTX.
How many shares of Seaport Therapeutics, Inc. are outstanding?
53.5 million shares as of October 27, 2026, from its 10-Q filed November 2, 2026.
How many business segments does Seaport Therapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 2, 2026.
Have Seaport Therapeutics, Inc. insiders traded stock recently?
Since June 22, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $335K on Forms 4 and 5. The most recent: Denice Torres (Director) bought 5,000 shares on November 3, 2026.